Jack Zeineh

Dr. Zeineh brings 25 years of technology development, entrepreneurialism, operating and investing experience to Amerigo. He currently focuses his time on various early-stage and private equity investment opportunities as well as advisory engagements. Dr. Zeineh is currently providing intellectual property strategy development to Acorns, a VC-backed investment software company. He is also advising a med-tech incubation group at a prominent New York City-based healthcare system. Dr. Zeineh has spent the majority of his career as an entrepreneur and operator, namely as the founder of Trestle, the largest digital pathology solution provider in the industry prior to its acquisition by Clarient (subsidiary of General Electric). He also served as the Chief Scientific Officer at Clarient and Chief Scientific Officer and Chief Technology Officer for Carl Zeiss Microimaging AIS. In addition, Dr. Zeineh was an early investor in the Southern California apparel company RVCA (acquired by Billabong).